This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Tedeschi A, Cairoli R, Marenco P, Nosari A, Tresoldi E et al. Molecular remission and reconstitution of a full chimera with arsenic trioxide in a patient with acute promyelocytic leukemia relapsed after allogeneic bone marrow transplantation. Leukemia 2002; 16: 2455–2456.
Avvisati G, Petti MC, Lo-Coco F, Vegna ML, Amadori S, Baccarani M et al. Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up. Blood 2002; 100: 3141–3146.
Diverio D, Rossi V, Avvisati G, De Santis S, Pistilli A, Pane F et al. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARα fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicentre ‘AIDA’ trial. Blood 1998; 92: 784–789.
Lo Coco F, Diverio D, Avvisati G, Petti MC, Meloni G, Pogliani EM et al. Therapy of molecular relapse in acute promyelocytic leukemia. Blood 1999; 94: 2225–2229.
Applegate TL, Iland HJ, Mokany E, Todd AV . Molecular monitoring of acute promyelocytic leukemia using DzyNA reverse transcription-PCR. Clin Chem 2002; 48: 1858–1860.
Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001; 19: 3852–3860.
Lallemand-Breitenbach V, Guillemin MC, Janin A, Daniel MT, Degos L, Kogan SC et al. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med 1999; 189: 1043–1052.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Grigg, A., Kimber, R. & Szer, J. Prolonged molecular remission after arsenic trioxide and all-trans retinoic acid for acute promyelocytic leukemia relapsed after allogeneic stem cell transplantation. Leukemia 17, 1916–1917 (2003). https://doi.org/10.1038/sj.leu.2403050
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2403050
This article is cited by
-
Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia
Leukemia (2012)
-
The early addition of arsenic trioxide versus high-dose arabinoside is more effective and safe as consolidation chemotherapy for risk-tailored patients with acute promyelocytic leukemia: multicenter experience
Medical Oncology (2012)
-
Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase Cδ
Leukemia (2007)
-
Reply to A Grigg et al
Leukemia (2003)